业界动态国内医卫资讯
奥希替尼-赛沃替尼联合方案提升MET阳性非小细胞肺癌患者生存期
Medscape News · 2026-10-29 22:40
摘要
该靶向联合方案延长了在接受奥希替尼治疗后出现疾病进展的MET变异肺癌患者的无进展生存期和总生存期——提示这可能成为一种新的治疗选择。Medscape医学新闻
English
Osimertinib-Savolitinib Boosts Survival in MET+ NSCLC
The targeted doublet extended progression-free and overall survival in patients with MET-altered lung cancer that had progressed on osimertinib -- pointing to a potential new treatment option. Medscape Medical News